Thera-SAbDab

CEMIPLIMAB

>   Structural Summary
TherapeuticCemiplimab
TargetPDCD1
Heavy ChainEVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedInovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sidney Kimmel Cancer Center, SillaJen Biotherapeutics, University of Texas M. D. Anderson Cancer Center
Conditions ApprovedSquamous cell cancer, Basal cell cancer, Non-small cell lung cancer
Conditions ActiveCervical cancer, Oropharyngeal cancer, Prostate cancer, Fallopian tube cancer, Glioblastoma, Multiple myeloma, Ovarian cancer, Peritoneal cancer, Solid tumours, Head and neck cancer, Malignant melanoma, Renal cell carcinoma
Conditions DiscontinuedB-cell lymphoma
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy